Introduction: Benign epilepsy with central-temporal spikes (BECTS) is the most common epileptic syndrome in childhood. It is an age-dependent, genetically determined and benign condition. The aim of this study is to describe the clinical course and prognosis in 60 patients with BECTS diagnosed in our hospital.
Patients And Methods: We made a retrospective review of patients diagnosed with BECTS in a University Hospital (1995-2009). They were divided into 2 groups: 1) Patients who met all BECTS classical criteria. 2) Patients who met all the criteria but one (less than 4 years; diurnal seizures; atypical EEG abnormalities).
Results: A total of 60 patients, 34 males and 26 females were included, with 31 patients in group 1 and 29 in group 2. The mean age at onset in group 1: 7.45 years, group 2: 6.55 years. Medical treatment was indicated in 32.2% of patients in group 1 and 41.3% in group 2. The outcome was favourable in the majority: 58% in group 1 and 62.1% in group 2 were free of seizures after 1 year. Average age in which it disappeared: 8.54 years in group 1 and 7.84 years in group 2. There were no statistically significant differences in any of these parameters.
Conclusions: Unlike that published by some authors, we have not identified any poor outcome factors in patients with BECTS in this study, meaning that an accurate diagnosis correlates with a good prognosis and excellent neurological outcome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.nrl.2011.07.009 | DOI Listing |
Curr Res Transl Med
January 2025
Department of Diabetology and Endocrinology, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India.
Drug repurposing is a promising strategy for managing cardiovascular disease (CVD) in geriatric populations, offering efficient and cost-effective solutions. CVDs are prevalent across all age groups, with a significant increase in prevalence among geriatric populations. The middle-age period (40-65 years) is critical due to factors like obesity, sedentary lifestyle, and psychosocial stress.
View Article and Find Full Text PDFDis Colon Rectum
February 2025
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio.
Background: Patients with Crohn's disease face an elevated risk of colorectal cancer, in part due to underlying chronic inflammation. Biologic therapy is the mainstay of medical treatment; however, the impact of treatment on colorectal cancer-related outcomes remains unclear.
Objective: To investigate the association between prior exposure to biologic treatment and colorectal cancer-related outcomes in patients with underlying Crohn's disease.
Dis Colon Rectum
February 2025
Department of General Surgery, Jinling Medical School of Nanjing Medical University, Nanjing, China.
Background: Even in the biological era, permanent stoma is not uncommon in patients with Crohn's Disease.
Objective: This study aimed to investigate the incidence and risk factors of permanent stoma in Crohn's disease patients and provide clinical evidence for reducing this disabling outcome.
Design: Consecutive patients with Crohn's disease who underwent ostomies in the past decade were reviewed.
Am J Manag Care
January 2025
RAND, 1776 Main St, Santa Monica, CA 90401. Email:
Objectives: Patient experience surveys are essential to measuring patient-centered care, a key component of health care quality. Low response rates in underserved groups may limit their representation in overall measure performance and hamper efforts to assess health equity. Telephone follow-up improves response rates in many health care settings, yet little recent work has examined this for surveys of Medicare enrollees, including those with Medicare Advantage.
View Article and Find Full Text PDFAm J Manag Care
January 2025
Arine, 595 Market St #2550, San Francisco, CA 94105. Email:
Objective: To assess the effects of a nurse-led personalized care plan on the duration of olaparib therapy among patients with cancer.
Study Design: Cohort study conducted from January 2020 to June 2022.
Methods: Data from an independent specialty pharmacy were used to identify patients 18 years and older with at least 1 olaparib (Lynparza) prescription who were at high risk for olaparib nonadherence as assessed using a pharmacy intake survey.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!